Lung Cancer
Volume 65, Issue 2 , Pages 187-191 , August 2009

A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer

Received 27 June 2008 ,Revised 27 October 2008 ,Accepted 2 November 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(08)00575-8

doi: 10.1016/j.lungcan.2008.11.002

Lung Cancer
Volume 65, Issue 2 , Pages 187-191 , August 2009

Article Tools

* Image Usage & Resolution